Date: 2016-08-10
Type of information: IPO
Company: Gemphiire Therapeutics
Investors:
Amount: $30 million
Funding type: IPO
Planned used:
Others:
- • On August 10, 2016, Gemphire Therapeutics announced the closing of its previously announced initial public offering of 3,000,000 shares of its common stock at a price to the public of $10.00 per share. In addition, Gemphire has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The shares began trading on the NASDAQ Global Market on August 5, 2016 under the ticker symbol "GEMP". The gross proceeds to Gemphire from the initial public offering were $30 million, before deducting underwriting discounts and commissions and estimated offering expenses.
- • On August 4, 2016, Gemphire Therapeutics announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a price to the public of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on August 5, 2016 under the ticker symbol "GEMP". The offering is expected to close on August 10, 2016, subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 shares of common stock. Jefferies and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity Inc. is acting as co-lead manager for the offering and Laidlaw & Company (UK) and LifeSci Capital are acting as co-managers.
Therapeutic area: Liver diseases - Hepatic diseases
Is general: Yes
